Advertisement
UK markets close in 4 hours 19 minutes

  • FTSE 100

    7,861.40
    +13.41 (+0.17%)
     

  • FTSE 250

    19,401.66
    +61.52 (+0.32%)
     

  • AIM

    743.80
    +0.68 (+0.09%)
     

  • GBP/EUR

    1.1688
    +0.0021 (+0.18%)
     

  • GBP/USD

    1.2480
    +0.0024 (+0.19%)
     

  • Bitcoin GBP

    49,791.65
    -740.64 (-1.47%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • CRUDE OIL

    81.87
    -0.82 (-0.99%)
     

  • GOLD FUTURES

    2,398.00
    +9.60 (+0.40%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     

  • DAX

    17,780.16
    +10.14 (+0.06%)
     

  • CAC 40

    8,015.19
    +33.68 (+0.42%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

EU Agency backs new drugs from GSK, Novartis, J&J

Reuters - UK Focus

LONDON, Feb 21 (Reuters) - European regulators said on Friday they had recommended approval of 10 drugs, six of which were for respiratory diseases including GlaxoSmithKline (Other OTC: GLAXF - news) 's Anoro and Laventair and Novartis (Xetra: NOT.DE - news) 's Ulunar Breezhaler.

The European Medicine Agency (EMA) also gave the green light to Vokanamet, a treatment for type 2 diabetes marketed by Johnson & Johnson (NYSE: JNJ - news) .

Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.